Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Other Non Operating Income (2023 - 2025)

CG Oncology filings provide 3 years of Other Non Operating Income readings, the most recent being -$53000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 983.33% to -$53000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$152000.0, a 5166.67% decrease, with the full-year FY2025 number at -$152000.0, down 5166.67% from a year prior.
  • Other Non Operating Income hit -$53000.0 in Q4 2025 for CG Oncology, up from -$100000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $8000.0 in Q1 2023 to a low of -$100000.0 in Q3 2025.
  • Median Other Non Operating Income over the past 3 years was -$4000.0 (2023), compared with a mean of -$17583.3.
  • Biggest five-year swings in Other Non Operating Income: soared 250.0% in 2024 and later crashed 4900.0% in 2025.
  • CG Oncology's Other Non Operating Income stood at -$4000.0 in 2023, then soared by 250.0% to $6000.0 in 2024, then tumbled by 983.33% to -$53000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$53000.0 (Q4 2025), -$100000.0 (Q3 2025), and -$4000.0 (Q2 2025) per Business Quant data.